Article Text
PDF
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Q Does risperidone prevent relapse compared with placebo for children with autism spectrum disorders?
METHODS
Design:
Randomised controlled trial.
Allocation:
Concealed.
Blinding:
Double blind.
Follow up period:
Thirty two weeks.
Setting:
Groningen and Utrecht University Child and Adolescent Psychiatry Centres; time period not stated.
Patients:
Thirty six children aged 5–17 years with an autism spectrum disorder (Autism Diagnostic Interview-Revised plus clinical judgement) enrolled in the open label phase, 24 children who responded to risperidone were randomised. Other enrolment criteria: at least moderate disruptive behaviour (tantrums, self-injury, and/or aggression) …
Footnotes
For correspondence: Dr Pieter W Troost, Child and Adolescent Psychiatry Center, Hanzeplein 1, 9713 GZ Groningen, the Netherlands; p.troost{at}accare.nl
Source of funding: Korczak Foundation.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.